- $41.45m
- $29.09m
- $1.12m
RenovoRx Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Renovorx Announces Pricing Of $12.1 Million Underwritten Public Offering Of Common Stock
Brief: Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
RenovoRx Inc reports results for the quarter ended in June - Earnings Summary
Brief: Renovorx Appoints Ryan Witt As Senior Vice President, Head Of Corporate Strategy And Partnerships
RenovoRx Inc reports results for the quarter ended in January - Earnings Summary
RenovoRx Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: RenovoRx Announces $11.1 Mln At Market Private Placement
RenovoRx Inc reports results for the quarter ended in December - Earnings Summary
RenovoRx Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Renovorx Says On February 21, Co Got Notice From Nasdaq
Brief: Renovorx Says James Ahlers Provided Notice To Co Of His Resignation As Chief Financial Officer, Effective Immediately
Brief: RenovoRx CEO Issues Letter to Shareholders
Brief: Renovorx Engages Oklahoma University (Ou) Health As First Clinical Site
Brief: RenovoRx Files New International Patent For Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
Brief: RenovoRx Q3 Net Income USD -1.421 Million
Brief: Renovorx Inc - On Oct 31, Co Received Formal Notice, The Staff Of The Nasdaq Had Granted The Co’S Request For Continued Listing On Nasdaq
Brief: Renovorx says Got Letter From Nasdaq That Co Was Not In Compliance With Minimum Stockholders Equity Requirement For Continued Listing